帕金森病伴骨质疏松症患者血清S100A6、S100A12水平及其临床意义

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1073 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To determine the levels of serum calcium-binding protein (S100) A6 and S100A12 in patients with Parkinson's disease (PD) and osteoporosis and analyze their clinical significance. Methods A total of 134 PD patients admitted to Shandong Provincial Corps Hospital of Chinese People's Armed Police Force from April 2021 to March 2024 were selected and divided into an osteoporosis group (n=53) and a non-osteoporosis group (n=81) according to the occurrence of osteoporosis. Pearson correlation analysis was used to analyze the relationship between serum S100A6, S100A12 and bone metabolism markers. Multivariate Logistic regression analysis was used to analyze the risk factors affecting osteoporosis in PD patients, and receiver operating characteristic (ROC) curve was drawn to analyze the predictive value of the two indicators for osteoporosis in PD patients. Results Among 134 PD patients, 53 cases developed osteoporosis(39.55%). Compared with non-osteoporosis group, serum levels of S100A6 and S100A12 in osteoporosis group increased (P<0.05). The type I procollagen amino-terminal propeptide (PINP) and 25-hydroxyvitamin D [25(OH)D] levels in osteoporosis group were lower than those in non-osteoporosis group, while the type I collagen C-terminal peptide (S-CTX) and β-collagen specific sequence (β-CTX) levels were higher than those in non-osteoporosis group (P<0.05). Pearson correlation analysis showed that serum S100A6 and S100A12 were negatively correlated with PINP and 25 (OH) D (P<0.05), but positively correlated with S-CTX and β-CTX (P<0.05). Multivariate Logistic regression analysis showed that old age, female, advanced disease and elevated serum S100A6 and S100A12 were independent risk factors for osteoporosis in PD patients (P<0.05). ROC curve showed that serum S100A6 and S100A12 alone predicted the AUC of osteoporosis in PD patients were 0.665 and 0.746 respectively, the combined predicted AUC was 0.913 (0.872-0.945), and the combined prediction efficiency was higher than that of single index (P<0.05). Conclusions Serum S100A6 and S100A12 are abnormally elevated in PD patients with osteoporosis and they are correlated with bone metabolism, which is helpful for screening PD patients with osteoporosis.

Key words： Parkinson's disease osteoporosis calcium-binding protein A6 calcium-binding protein A12 bone metabolism

Received: 11 December 2024

ZTFLH:

R742.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yang
	WANG Ke
	CHENG Gang
	LIU Jia

Cite this article:

LIU Yang,WANG Ke,CHENG Gang等. Serum levels of S100A6 and S100A12 in patients with Parkinson's disease and osteoporosis and their clinical significance[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(4): 319-324.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2025/V36/I4/319

[1]	Morris H R, Spillantini M G, Sue C M, et al. The pathogenesis of Parkinson's disease[J]. Lancet, 2024, 403(10423): 293-304.
[2]	Cattaneo C, Jost W H. Pain in Parkinson's disease: pathophysiology, classification and treatment[J]. J Integr Neurosci, 2023, 22(5): 132.
[3]	Feng S H, Huang Y P, Yeh K C, et al. Osteoporosis and the risk of Parkinson's disease: a nationwide, propensity score-matched, longitudinal follow-up study[J]. J Clin Endocrinol Metab, 2021, 106(2): e763-e771.
[4]	Kim T L, Byun S J, Seong M Y, et al. Fracture risk and impact of osteoporosis in patients with Parkinson's disease: a nationwide database study[J]. J Bone Miner Metab, 2022, 40(4): 602-612.
[5]	孙鹏, 张国华, 陈超斌, 等. 血清Irisin、SOST、H2S与膝骨关节炎合并骨质疏松症患者骨密度、骨代谢标志物的相关性及其预测价值[J]. 现代生物医学进展,2024, 24(10):1980-1984.
[6]	Lee S H, Ihn H J, Park E K, et al. S100 Calcium-binding protein P secreted from megakaryocytes promotes osteoclast maturation[J]. Int J Mol Sci, 2021, 22(11): 6129.
[7]	Wang T, Zhu G, Wang B, et al. Activation of hypoxia inducible factor-1 Alpha-mediated DNA methylation enzymes (DNMT3a and TET2) under hypoxic conditions regulates S100A6 transcription to promote lung cancer cell growth and metastasis[J]. Antioxid Redox Signal, 2024, 41(1-3): 138-151.
[8]	Yang F, Ma J, Zhu D, et al. The role of S100A6 in human diseases: molecular mechanisms and therapeutic potential[J]. Biomolecules, 2023, 13(7): 1139.
[9]	Chen L, Wang Y, Huang J, et al. Identification of immune-related hub genes in Parkinson's disease[J]. Front Genet, 2022, 13(7): 914645.
[10]	赵俊杰, 全璐璐, 张旭, 等. 升高咬合对骨质疏松大鼠TMJ滑膜中S100 A12表达影响[J]. 临床口腔医学杂志,2021, 37(11):647-650.
[11]	Goetz C G, Poewe W, Rascol O, et al. Movement disorder society task force report on the hoehn and yahr staging scale: status and recommendations[J]. Mov Disord, 2004, 19(9): 1020-1028.
[12]	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 帕金森病基层诊疗指南(2019年)[J]. 中华全科医师杂志,2020, 19(1):5-17.
[13]	Wáng Y X J, Griffith J F, Blake G M, et al. Revision of the 1994 World Health Organization T-score definition of osteoporosis for use in older East Asian women and men to reconcile it with their lifetime risk of fragility fracture[J]. Skeletal Radiol, 2024, 53(4): 609-625.
[14]	Goetz C G, Liu Y, Stebbins G T, et al. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the unified Parkinson's disease rating scale[J]. Mov Disord, 2016, 31(12): 1865-1873.
[15]	Folstein M F, Folstein S E, McHugh P R. “Mini-mental state”. a practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res, 1975, 12(3): 189-198.
[16]	Nasreddine Z S, Phillips N A, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53(4): 695-699.
[17]	《中国老年骨质疏松症诊疗指南2023》工作组,中国老年学和老年医学学会骨质疏松分会,中国医疗保健国际交流促进会骨质疏松病学分会,等. 中国老年骨质疏松症诊疗指南(2023)[J]. 中华骨与关节外科杂志,2023,16(10):865-885.
[18]	李晴, 周庆博. 帕金森病合并骨质疏松的研究进展[J]. 中华老年医学杂志,2021, 40(4):509-512.
[19]	Cui Y, Lv B, Li Z, et al. Bone-targeted biomimetic nanogels re-establish osteoblast/osteoclast balance to treat postmenopausal osteoporosis[J]. Small, 2024, 20(6): e2303494.
[20]	Filipek A, Lesniak W. S100A6 and its brain ligands in neurodegenerative disorders[J]. Int J Mol Sci, 2020, 21(11): 3979.
[21]	Lachén-Montes M, González-Morales A, Iloro I, et al. Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling[J]. Neurobiol, 2019,73: 123-134.
[22]	袁赤亭. S100A4和S100A6在去势大鼠骨组织中表达及意义[D].温州:温州医科大学, 2014.
[23]	李树栋, 梁学振, 李刚. 生物信息学与机器学习识别诊断绝经后骨质疏松症患者的生物标志物[J]. 中国骨质疏松杂志,2023, 29(9):1310-1314.
[24]	许富贵, 乙红艳, 欧洲, 等. 骨转换标志物PINP和β-CTX在帕金森病患者发生骨质疏松中的预测价值[J]. 南京医科大学学报(自然科学版),2023, 43(8):1128-1132.
[25]	Föger-Samwald U, Kerschan-Schindl K, Butylina M, et al. Age related osteoporosis: targeting cellular senescence[J]. Int J Mol Sci, 2022, 23(5): 2701.
[26]	闫秀杰, 庄雯媛, 张蕊,等.地舒单抗联合雷洛昔芬对绝经后骨质疏松患者性激素结合蛋白、骨硬化蛋白水平的影响[J].武警医学,2024, 35(8): 650-653.
[27]	Fan Y, Li Q, Liu Y, et al. Sex- and age-specific prevalence of osteopenia and osteoporosis: sampling survey[J]. JMIR Public Health Surveill, 2024, 10(2): e48947.
[28]	周曼曼, 徐志强, 高雯雯, 等. 血清胰岛素样生长因子1与帕金森病伴骨质疏松的相关性研究[J]. 国际神经病学神经外科学杂志,2023, 50(6):7-12.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(4): 349-352.